DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Institution	Shares	Value	Change
Mpm Bioimpact	3,666,284	$60M	DECREASED
Siren,	1,857,362	$30M	UNCHANGED
Vivo Capital	1,844,758	$30M	DECREASED
Perceptive Advisors	1,653,350	$27M	INCREASED
Baker Bros. Advisors	1,461,425	$24M	UNCHANGED

DBV Technologies S.A. American Depositary Shares (DBVT) Ownership & Trading Activity

Top Institutional Holders